Maxamine histamine dihydrochloride histamine receptor agonist regulatory update

The FDA's Oncologic Drugs Advisory Committee (ODAC) unanimously recommended against approval of Maxamine

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE